Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Piperidine derivatives as inhibitors of ubiquitin specific protease 7

a protease and inhibitor technology, applied in the direction of organic chemistry, organic active ingredients, drug compositions, etc., can solve the problems of poor survival, severe clinical utility, and correlation with tumor aggressiveness, and achieve the effect of greater activity

Active Publication Date: 2019-08-22
ALMAC DISCOVERY LIMITED
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a compound that can inhibit the activity of a protein called USP7, which is associated with various diseases such as cancer, diabetes, and viral infections. The compound can be used as a treatment for these conditions either alone or in combination with other therapies like radiation and chemotherapy. The patent also provides a pharmaceutical composition containing the compound for use in therapy.

Problems solved by technology

Although effective, their clinical utility has however been severely limited due to poor selectivity and acute toxicity issues.
Overexpression typically correlates with tumor aggressiveness and poor survival.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Piperidine derivatives as inhibitors of ubiquitin specific protease 7
  • Piperidine derivatives as inhibitors of ubiquitin specific protease 7
  • Piperidine derivatives as inhibitors of ubiquitin specific protease 7

Examples

Experimental program
Comparison scheme
Effect test

example 1

oro-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrimidin-4(3H)-one (Intermediate A)

[0494]

[0495]A suspension of 6-chloropyrimidin-4(3H)-one (U.S. Pat. Appl. Publ., 20090149466, 11 Jun. 2009) (200 mg, 1.53 mmol), Epoxide 2 (397 mg, 1.53 mmol) and DIPEA (401 μl, 2.30 mmol) in DMF (3 mL) was heated at 80° C. for 16 h. The reaction mixture was then allowed to cool to RT and was quenched by the addition of saturated NH4Cl(aq) (20 mL). The mixture was extracted with EtOAc (3×20 mL), the combined organic extracts were dried over Na2SO4, concentrated, and the residue was purified by flash chromatography (Biotage 25 g KP-Sil, 0-100% EtOAc in PE then 0-30% MeOH in EtOAc) to give the title compound (350 mg, 59%) as a pale yellow solid. LCMS (Method A): RT=1.11 min, m / z=390, 392 [M+H]+. 1H NMR (300 MHz, methanol-d4, this molecule appears as two conformers A and B in a 2:3 ratio respectively): δ 8.28 (s, 0.4H (conformer A)), 8.24 (s, 0.6H (conformer B)), 7.38-7.13 (m, 5H), 6.58 (s, 1...

example 2

-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-6-(pyridin-4-yl)pyrimidin-4(3H)-one

[0496]

[0497]General procedure 5 using Intermediate A (25 mg, 0.064 mmol), pyridin-4-ylboronic acid (12 mg, 0.096 mmol), Na2CO3 (14 mg, 0.128 mmol), Pd(PPh3)4(3.7 mg, 3.21 μmol), 1,4-dioxane (0.4 mL) and water (0.16 mL) in a sealed tube under microwave heating at 150° C. for 10 min gave the title compound (24 mg, 86%) as a colourless solid. LCMS (Method A): RT=0.81 min, m / z=433 [M+H]+. 1H NMR (300 MHz, CDCl3, this molecule appears as two conformers A and B in a 2:3 ratio respectively): δ 8.76-8.62 (m, 2H), 8.23 (s, 0.4H (conformer A)), 8.13 (s, 0.6H (conformer B)), 7.83-7.71 (m, 2H), 7.40-7.13 (m, 5H), 6.95 (s, 1H), 4.49-4.23 (m, 1H), 4.21-3.80 (m, 3H), 3.67-3.47 (m, 1H), 3.44-2.87 (m, 3H), 2.72-2.59 (m, 1H), 2.59-2.42 (m, 1H), 1.68-1.21 (m, 7H), 0.94-0.71 (m, 0.6H (conformer B only)).

example 3

-Hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-6-(1H-pyrazol-5-yl)pyrimidin-4(3H)-one

[0498]

[0499]General procedure 5 using Intermediate A (25 mg, 0.064 mmol), (1H-pyrazol-5-yl)boronic acid (11 mg, 0.096 mmol), Na2CO3 (14 mg, 0.128 mmol), Pd(PPh3)4(3.7 mg, 3.21 μmol), 1,4-dioxane (0.4 mL) and water (0.16 mL) in a sealed tube under microwave heating at 150° C. for 10 min gave the title compound (19 mg, 70%) as a colourless solid. LCMS (Method A): RT=0.921 min, m / z=422 [M+H]+. 1H NMR (300 MHz, CDCl3, this molecule appears as two conformers A and B in a 2:3 ratio respectively): δ 8.28 (s, 0.4H (conformer A)), 8.18 (s, 0.6H (conformer B)), 7.65-7.56 (m, 1H), 7.37-7.14 (m, 5H), 7.05-6.92 (m, 1H), 6.81-6.71 (m, 1H), 4.44-4.20 (m, 1H), 4.21-3.79 (m, 2H), 3.65-2.86 (m, 4H), 2.71-2.57 (m, 1H), 2.57-2.41 (m, 1H), 1.63-1.21 (m, 7H), 0.90-0.73 (m, 0.6H (conformer B only)).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molar densityaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.

Description

[0001]The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.BACKGROUND OF THE INVENTION[0002]Over the past three decades, protein ubiquitination has emerged as an important post-translational modification with roles in a plethora of cellular processes including: proteolysis, gene expression, DNA repair, immune response, metabolism and cell-cycle regulation. Dysregulation of the ubiquitin proteasome system (UPS) has also been implicated in the pathogenesis of multiple human diseases including (but not limited to): cancer (Hoeller et al., Nat. Rev. Cancer (2006), 6, 776-788), viral infection (Gao et al., Can. J. Physiol. Pharmacol. (2006), 84, 5-14), metabolic or neurodegenerative disorders (Loosdregt et al., Immunity (2013), 39, 259-271; Rubinsztein et al., Nature (2006), 443, 780-786) as well as immune and inflammatory-related medical conditions (Wang et al., Cell Mol. Immunol. (2006), 3, 255-261; Corn J. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D487/04C07D401/14C07D401/06C07D473/00C07D487/08C07D471/10C07D401/04C07D513/04C07D493/04C07D413/14C07D405/14C07D491/107A61P35/00
CPCC07D487/04C07D401/14C07D401/06C07D473/00C07D487/08C07D471/10C07D401/04C07D513/04C07D493/04C07D413/14C07D405/14C07D491/107A61P35/00C07D403/04C07D471/04C07D491/04A61K31/506A61K2300/00A61K31/519A61K31/522A61K45/06
Inventor O'DOWD, COLINHARRISON, TIMHEWITT, PETERROUNTREE, SHANEHUGUES, MIELBURKAMP, FRANKJORDAN, LINDA DUNCANHELM, MATTHEWBROCCATELLI, FABIOCRAWFORD, JAMES JOHNGAZZARD, LEWISWERTZ, INGRIDLEE, WENDY
Owner ALMAC DISCOVERY LIMITED
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com